CN116570538A - 一种含牛油果树果脂提取物成分的润肤护理组合物 - Google Patents
一种含牛油果树果脂提取物成分的润肤护理组合物 Download PDFInfo
- Publication number
- CN116570538A CN116570538A CN202310415440.2A CN202310415440A CN116570538A CN 116570538 A CN116570538 A CN 116570538A CN 202310415440 A CN202310415440 A CN 202310415440A CN 116570538 A CN116570538 A CN 116570538A
- Authority
- CN
- China
- Prior art keywords
- parts
- skin
- butter
- polydimethylsiloxane
- skin care
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000284 extract Substances 0.000 title claims abstract description 43
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 235000014121 butter Nutrition 0.000 title claims abstract description 25
- 241001135917 Vitellaria paradoxa Species 0.000 title claims description 17
- 235000018936 Vitellaria paradoxa Nutrition 0.000 title claims description 17
- -1 triterpene ester Chemical class 0.000 claims abstract description 51
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 26
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 24
- 239000002994 raw material Substances 0.000 claims abstract description 23
- 229940082500 cetostearyl alcohol Drugs 0.000 claims abstract description 22
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims abstract description 22
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 21
- 239000003974 emollient agent Substances 0.000 claims abstract description 21
- 230000003020 moisturizing effect Effects 0.000 claims abstract description 21
- 240000002134 Pentadesma butyracea Species 0.000 claims abstract description 20
- 235000000857 Pentadesma butyracea Nutrition 0.000 claims abstract description 20
- 230000003750 conditioning effect Effects 0.000 claims abstract description 20
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000002562 thickening agent Substances 0.000 claims abstract description 8
- 235000016108 Argania sideroxylon Nutrition 0.000 claims abstract description 5
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229930182478 glucoside Natural products 0.000 claims abstract description 5
- 150000008131 glucosides Chemical class 0.000 claims abstract description 5
- 229930003799 tocopherol Natural products 0.000 claims abstract description 5
- 229960001295 tocopherol Drugs 0.000 claims abstract description 5
- 239000011732 tocopherol Substances 0.000 claims abstract description 5
- 235000010384 tocopherol Nutrition 0.000 claims abstract description 5
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims abstract description 5
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 51
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 51
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical group CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 34
- 235000019197 fats Nutrition 0.000 claims description 18
- 229920006037 cross link polymer Polymers 0.000 claims description 17
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 17
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical group CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 17
- 229940032094 squalane Drugs 0.000 claims description 17
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims description 17
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 17
- 229920002554 vinyl polymer Polymers 0.000 claims description 17
- 235000008390 olive oil Nutrition 0.000 claims description 16
- 239000004006 olive oil Substances 0.000 claims description 16
- 239000003921 oil Substances 0.000 claims description 7
- 235000019198 oils Nutrition 0.000 claims description 7
- 239000002537 cosmetic Substances 0.000 claims description 6
- 244000025272 Persea americana Species 0.000 claims description 5
- 235000008673 Persea americana Nutrition 0.000 claims description 5
- 244000125300 Argania sideroxylon Species 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 3
- 229940057910 shea butter Drugs 0.000 claims description 3
- 239000002699 waste material Substances 0.000 claims description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims 15
- 229940008099 dimethicone Drugs 0.000 claims 3
- 240000007817 Olea europaea Species 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 abstract description 15
- 201000008937 atopic dermatitis Diseases 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 15
- 208000003251 Pruritus Diseases 0.000 abstract description 10
- 230000004054 inflammatory process Effects 0.000 abstract description 8
- 206010061218 Inflammation Diseases 0.000 abstract description 7
- 230000007803 itching Effects 0.000 abstract description 7
- 208000024891 symptom Diseases 0.000 abstract description 3
- 230000008728 vascular permeability Effects 0.000 abstract description 3
- 230000024883 vasodilation Effects 0.000 abstract description 3
- 241001673902 Argania spinosa Species 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 54
- 238000012360 testing method Methods 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 5
- 201000004624 Dermatitis Diseases 0.000 description 5
- 230000004888 barrier function Effects 0.000 description 5
- 230000000770 proinflammatory effect Effects 0.000 description 5
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 4
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 210000002510 keratinocyte Anatomy 0.000 description 4
- 239000000401 methanolic extract Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108090000176 Interleukin-13 Proteins 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 238000005260 corrosion Methods 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 description 2
- 240000000902 Diospyros discolor Species 0.000 description 2
- 235000003115 Diospyros discolor Nutrition 0.000 description 2
- 101000853002 Homo sapiens Interleukin-25 Proteins 0.000 description 2
- 101001128431 Homo sapiens Myeloid-derived growth factor Proteins 0.000 description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 2
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 238000005299 abrasion Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 230000000050 nutritive effect Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000001732 sebaceous gland Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 229940122739 Calcineurin inhibitor Drugs 0.000 description 1
- 101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 description 1
- 102100024123 Calcineurin-binding protein cabin-1 Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102100028314 Filaggrin Human genes 0.000 description 1
- 101710088660 Filaggrin Proteins 0.000 description 1
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 description 1
- 101000988424 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4B Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 101710181613 Interleukin-31 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 102000018745 NF-KappaB Inhibitor alpha Human genes 0.000 description 1
- 108010052419 NF-KappaB Inhibitor alpha Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000035999 Recurrence Diseases 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 206010048222 Xerosis Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000003766 afferent neuron Anatomy 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 102100029168 cAMP-specific 3',5'-cyclic phosphodiesterase 4B Human genes 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Natural products COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- XJQPQKLURWNAAH-UHFFFAOYSA-N dihydrocapsaicin Chemical compound COC1=CC(CNC(=O)CCCCCCC(C)C)=CC=C1O XJQPQKLURWNAAH-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000008718 systemic inflammatory response Effects 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/31—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/342—Alcohols having more than seven atoms in an unbroken chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/604—Alkylpolyglycosides; Derivatives thereof, e.g. esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/89—Polysiloxanes
- A61K8/891—Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/89—Polysiloxanes
- A61K8/895—Polysiloxanes containing silicon bound to unsaturated aliphatic groups, e.g. vinyl dimethicone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/48—Thickener, Thickening system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cosmetics (AREA)
Abstract
本发明涉及一种护肤品，具体为一种含牛油果树果脂提取物成分的润肤护理组合物，由以下原料组成：皮肤调理剂、增稠剂、润肤剂、乳化剂、润肤剂一、润肤剂二、润肤剂三、润肤剂四和润肤剂五，其中，皮肤调理剂为牛油果树果脂提取物、刺阿干树仁油、废麦芽粕蜡和生育酚的混合，乳化剂为鲸蜡硬脂醇和鲸蜡硬脂基葡糖苷的混合。本发明中，牛油果树果脂提取物中的三萜烯酯成分具有降低血管舒张和血管渗适的机率，有效舒缓瘙痒，发红等症状，与润肤剂、增稠剂相结合，起到舒缓瘙痒、祛除炎症与润肤的功效。采用多种润肤成分复配，发挥协同增效作用，起到优异的润肤作用，在治疗特应性皮炎中发挥辅助作用。
Description
技术领域
本发明涉及一种护肤品原料，具体为一种含牛油果树果脂提取物成分的润肤护理组合物。
背景技术
特应性皮炎(Atopic dematitis，AD) 又称为 “特异性湿疹”，是常见的一种慢性复发性炎性皮肤 病，发病与遗传和环境因素密切相关，最基本的特征 是皮肤干燥、慢性湿疹样皮炎、剧烈瘙痒。
皮肤生物学研究表明皮肤屏障功能缺陷是AD发病的关键因素，神经酰胺缺乏是屏障功能缺陷主要原因之一，出现角质层含水量少、经表皮水分丢失增加，AD皮脂腺发生变化，分泌脂质减少、pH升高等，导致皮肤出现干燥、脱屑，皮肤感觉神经纤维密度增加，瘙痒加剧。正确沐浴及使用润肤剂在AD治疗中非常重要。发作期以外用糖皮质激素、钙调磷酸酶抑制剂为主，辅以医学保湿霜，减轻疾病的严重程度，改善皮损区外观。缓解期可单独使用医学润肤剂，促进皮肤屏障恢复，维持病情稳定，减少复发率。
医学类保湿及修复屏障类护肤品耐受性好，从环境中吸收水分，补充角质层散失的水分及一定的脂质成分，在皮肤表面形成薄层油膜，重建化学/物理屏障，防止水分丢失，从而达到保湿润肤的功效，预防AD疾病复发，提高生活质量。为此，我们提出一种含牛油果树果脂提取物成分的润肤护理组合物。
发明内容
本发明的目的是提供一种含牛油果树果脂提取物成分的润肤护理组合物，牛油果树果脂提取物中的三萜烯酯成分具有降低血管舒张和血管渗适的机率，有效舒缓瘙痒，发红等症状，与润肤剂、增稠剂相结合，起到舒缓瘙痒、祛除炎症与润肤的功效。
为了实现上述目的，本发明采用以下技术方案
一种含牛油果树果脂提取物成分的润肤护理组合物，由以下原料组成：皮肤调理剂、增稠剂、润肤剂、乳化剂、润肤剂一、润肤剂二、润肤剂三、润肤剂四和润肤剂五，其中，皮肤调理剂为牛油果树果脂提取物、刺阿干树仁油、废麦芽粕蜡和生育酚的混合，乳化剂为鲸蜡硬脂醇和鲸蜡硬脂基葡糖苷的混合。
优选的，增稠剂为鲸蜡硬脂醇，润肤剂一为辛酸/癸酸甘油三酯，润肤剂二为聚二甲基硅氧烷，润肤剂三为油橄榄果油，润肤剂四为聚二甲基硅氧烷/乙烯基聚二甲基硅氧烷交联聚合物，润肤剂五为角鲨烷。
优选的，一种含牛油果树果脂提取物成分的润肤护理组合物，以重量份计，由以下原料组成：
皮肤调理剂1-5份、鲸蜡硬脂醇1-5份、辛酸/癸酸甘油三酯1-5份、乳化剂1-5份、聚二甲基硅氧烷0.1-1份、油橄榄果油0.1-1份、聚二甲基硅氧烷/乙烯基聚二甲基硅氧烷交联聚合物0.1-1份和角鲨烷0.1-1份。
优选的，一种含牛油果树果脂提取物成分的润肤护理组合物，以重量份计，由以下原料组成：
皮肤调理剂1份、鲸蜡硬脂醇2份、辛酸/癸酸甘油三酯1份、乳化剂2份、聚二甲基硅氧烷1份、油橄榄果油0.2份、聚二甲基硅氧烷/乙烯基聚二甲基硅氧烷交联聚合物0.2份和角鲨烷0.2份。
优选的，一种含牛油果树果脂提取物成分的润肤护理组合物，以重量份计，由以下原料组成：
皮肤调理剂3份、鲸蜡硬脂醇2份、辛酸/癸酸甘油三酯2份、乳化剂2份、聚二甲基硅氧烷1份、油橄榄果油0.5份、聚二甲基硅氧烷/乙烯基聚二甲基硅氧烷交联聚合物0.5份和角鲨烷0.2份。
优选的，一种含牛油果树果脂提取物成分的润肤护理组合物，以重量份计，由以下原料组成：
皮肤调理剂5份、鲸蜡硬脂醇5份、辛酸/癸酸甘油三酯5份、乳化剂1份、聚二甲基硅氧烷0.5份、油橄榄果油0.6份、聚二甲基硅氧烷/乙烯基聚二甲基硅氧烷交联聚合物0.3份和角鲨烷0.2份。
优选的，所述皮肤调理剂为重量比（4-8）：（2-4）：（1-3）：2的牛油果树果脂提取物、刺阿干树仁油、废麦芽粕蜡和生育酚的混合。
优选的，所述乳化剂为重量比2：（3—5）的鲸蜡硬脂醇和鲸蜡硬脂基葡糖苷的混合。
一种含牛油果树果脂提取物成分的润肤护理组合物的应用，作为原料应用于润肤护理类化妆品中和应用于医用润肤类组合物中。
优选的，作为原料应用于润肤护理乳液中。
本发明的有益效果：
1、本发明中，牛油果树果脂提取物中的三萜烯酯成分具有降低血管舒张和血管渗适的机率，有效舒缓瘙痒，发红等症状，与润肤剂、增稠剂相结合，起到舒缓瘙痒、祛除炎症与润肤的功效。
2、本发明中，采用多种润肤成分复配，发挥协同增效作用，起到优异的润肤作用，在治疗特应性皮炎中发挥辅助作用，在皮肤表面形成薄层油膜，重建化学/物理屏障，防止水分丢失，从而达到保湿润肤的功效，预防AD疾病复发，提高生活质量。
实施方式
下面对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例仅仅是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其它实施例，都属于本发明保护的范围。
实施例1
一种含牛油果树果脂提取物成分的润肤护理组合物，以重量份计，由以下原料组成：
皮肤调理剂1份、鲸蜡硬脂醇2份、辛酸/癸酸甘油三酯1份、乳化剂2份、聚二甲基硅氧烷1份、油橄榄果油0.2份、聚二甲基硅氧烷/乙烯基聚二甲基硅氧烷交联聚合物0.2份和角鲨烷0.2份。
实施例2
一种含牛油果树果脂提取物成分的润肤护理组合物，以重量份计，由以下原料组成：
皮肤调理剂3份、鲸蜡硬脂醇2份、辛酸/癸酸甘油三酯2份、乳化剂2份、聚二甲基硅氧烷1份、油橄榄果油0.5份、聚二甲基硅氧烷/乙烯基聚二甲基硅氧烷交联聚合物0.5份和角鲨烷0.2份。
实施例3
一种含牛油果树果脂提取物成分的润肤护理组合物，以重量份计，由以下原料组成：
皮肤调理剂5份、鲸蜡硬脂醇5份、辛酸/癸酸甘油三酯5份、乳化剂1份、聚二甲基硅氧烷0.5份、油橄榄果油0.6份、聚二甲基硅氧烷/乙烯基聚二甲基硅氧烷交联聚合物0.3份和角鲨烷0.2份。
实施例4
一种含牛油果树果脂提取物成分的润肤护理组合物，以重量份计，由以下原料组成：
皮肤调理剂2份、鲸蜡硬脂醇3份、辛酸/癸酸甘油三酯2份、乳化剂2份、聚二甲基硅氧烷0.2份、油橄榄果油0.3份、聚二甲基硅氧烷/乙烯基聚二甲基硅氧烷交联聚合物0.5份和角鲨烷0.5份。
实施例5
一种含牛油果树果脂提取物成分的润肤护理组合物，以重量份计，由以下原料组成：
皮肤调理剂4份、鲸蜡硬脂醇1份、辛酸/癸酸甘油三酯3份、乳化剂2份、聚二甲基硅氧烷0.5份、油橄榄果油0.8份、聚二甲基硅氧烷/乙烯基聚二甲基硅氧烷交联聚合物0.8份和角鲨烷0.1份。
实施例6
一种含牛油果树果脂提取物成分的润肤护理组合物，以重量份计，由以下原料组成：
皮肤调理剂3份、鲸蜡硬脂醇2份、辛酸/癸酸甘油三酯4份、乳化剂1.5份、聚二甲基硅氧烷0.3份、油橄榄果油1份、聚二甲基硅氧烷/乙烯基聚二甲基硅氧烷交联聚合物1份和角鲨烷0.5份。
实施例7
一种含牛油果树果脂提取物成分的润肤护理组合物，以重量份计，由以下原料组成：
皮肤调理剂3份、鲸蜡硬脂醇2份、辛酸/癸酸甘油三酯5份、乳化剂1份、聚二甲基硅氧烷0.5份、油橄榄果油0.5份、聚二甲基硅氧烷/乙烯基聚二甲基硅氧烷交联聚合物0.5份和角鲨烷0.1份。
试验例一
将实施例1-7制备的一种含牛油果树果脂提取物成分的润肤护理组合物进行检测，检测项目包括有无异味，保质期，细菌检测，重金属检测和毒性检测，结果如下。
表一
由试验结果分析可知，本发明制备的一种含牛油果树果脂提取物成分的润肤护理组合物符合国家化妆品卫生标准。
试验例二
将实施例1-7制备的一种含牛油果树果脂提取物成分的润肤护理组合物进行检测,检测项目包括热稳定性，光照稳定性，防腐挑战试验，舒缓效果、修复效果和保湿性，结果如下。
表二
由试验结果分析可知，本发明制备的一种含牛油果树果脂提取物成分的润肤护理组合物具有皮肤修护效果和舒缓效果，具有较好的保湿性，修复了清洁过度的皮肤，其中以实施例2效果最好。
本发明的原理在于：T细胞亚群包括Th1和Th2，而湿疹的发病与T细胞亚群的平衡失调有关，根据《中国特应性皮炎诊疗指南（2020版）》得知，Th2 型炎症是AD 的基础特征，而IL-4和IL-13是介导AD发病的重要细胞因子。Th2细胞主要分泌IL-4、IL-5、IL-13、IL-25、IL-31等。Th2细胞因子异常分泌与湿摩的发生、发展以及预后密切相关。Th2相关促炎因子：TSLP和IL-33，TSLP 是一种上皮细胞衍生因子，为 IL-7 类似物，参与 Th2疫应答失衡，是Th2 型免疫应答关键"引发剂"主要表达于上皮细胞和角质形成细胞。IL-33+ ST2+ 细胞的主要来源有角质形成细胞和内皮细胞。IL-33-ST2 途径则在免疫炎症反应中扮演了重要角色。高水平 IL-33 与脱落和干燥症显著相关，并且能下调角质形成细胞中的聚丝蛋白，从而影响皮肤内的屏障功能。IL-33 逐渐成为过敏性炎症，诸如哮喘和湿摩的新兴关键因素。IL-33 能上调细胞核中 NF-"B p65 亚基，促进内皮细胞的炎症，并且作为促炎因子与受体ST2 结合发挥作用。Th2细胞因子包括IL-25、IL-4、IL-5、IL-13。
湿疹的致炎因子还包括：TRPV-1，TRPV-1主要表达在传入神经元、角质形成细胞、树突状细胞和肥大细胞，某些瘙痒和疼痛调节因子，如辣椒碱或者类花生酸类物质、组胺、ATP 等，能够激活或者致敏TRPV-1，参与 AD 瘙痒的形成。PDE4，PDE4B 作为 PDE4 炎症调控的主要亚型，在激活肿瘤坏死因子 α 反应中起着至关重要的作用。TNF-α，TNF－ α 属于前炎症因子，一般由单核细胞巨噬细胞等分泌合成，参与一系列的炎症过程。AD 中肥大细胞的脱颗粒可能是通过 TNF － α 和组胺诱导角质形成细胞中细胞间粘附分子 ICAM－ 1的表达增加导致的。IL-1，IL-l是一种在局部和全身炎症反应中起核心作用的细胞因子，IL—l的表达与炎症程度正相关，可作为临床上判断炎症性疾病严重程度和疗效的指标。表皮活化后释放出IL一1，接着通过诱导多种细胞因子、前炎症介质和黏附分子促进皮肤炎症反应的发生。
本发明中，牛油果树果脂提取物，是从牛油果树的果实中提取而来，其中的天然保湿因子和从皮脂腺中提取的保湿组分具有相同的成分，因此也被视为最有效的天然保湿剂和调理剂。牛油果作为一种营养价值很高的水果，含多种维生素、丰富的脂肪和蛋白质，钠、钾、镁、钙等含量也高。提取的牛油果树果脂营养价值类似小麦胚芽油。含有不饱和脂肪酸、亚麻仁油酸，富含B族维生素、维生素E，此外还含有很好的护肤成分植物甾醇。
牛油果树果脂的功效，1）锁水保湿，是天然的植物乳化剂，可以在表层肌肤形成乳状隔离层，加速营养物质的渗透，具有强大的锁水保湿功能。2）抗氧化，牛油果树果脂含有维生素A、维生素E、维生素B6、蛋白质等元素，是天然的抗氧化剂。3）抵御紫外线，含有肉桂酸酯，用于防晒产品中可以防止紫外线照射对皮肤的伤害，而牛油果树果脂中的天然乳胶还可以防止由阳光照射引起的皮肤过敏。
牛油果树果脂提取物的抗炎作用主要通过抑制核因子 κB（NF-κB）、诱导型一氧化氮合（iNOS）、黏附分子（细胞间黏附分子-1 和血管细胞黏附分子-1）、肿瘤坏死因子（TNF-α）、白细胞介素-6（IL-6）和 IL-8 等细胞因子水平，同时促进 IL-4 和 IL-10 的产生实现。
Verma 等采用了脂多糖（LPS）诱导的鼠巨噬细胞系 J774 研究乳油木树脂甲醇提取物的抗炎机制。研究结果表明：甲醇提取物处理模型能显著地降低 LPS诱导的一氧化氮（NO）、TNF-α、IL-1β 和 IL-12 的水平，并呈剂量依赖关系。此外，促炎症酶、iNOS 和 COX-2也被抑制。上述抗炎作用是由于树脂甲醇提取物有效抑制了 NF-κB 抑制蛋白（IκBα）的磷酸化，从而抑制了 iNOS、COX-2、TNF-α、IL-1β 和 IL-12 的信使 RNA（mRNA）和蛋白的表达。这些发现直接从分子水平上解释了乳油木树脂甲醇提取物抗炎活性机制。
需要说明的是，本发明试验例是按照2007年《化妆品卫生规范》和2015年《化妆品安全技术规范》为参照标准，检测方法参考GB/T 13531.1-2008，防腐挑战试验参照PCPC(美国个人护理用品协会，原称CTFA)推荐的为期28天的防腐单次挑战试验方法，舒缓效果和清洁效果采用《化妆品安全技术规范2015版》中，第七章人体安全性检验方法中的试验方法进行试验。
在本说明书的描述中，参考术语“一个实施例”、“示例”、“具体示例”等的描述意指结合该实施例或示例描述的具体特征、结构、材料或者特点包含于本发明的至少一个实施例或示例中。在本说明书中，对上述术语的示意性表述不一定指的是相同的实施例或示例。而且，描述的具体特征、结构、材料或者特点可以在任何的一个或多个实施例或示例中以合适的方式结合。
最后需要说明的是，以上公开的本发明优选实施例只是用于帮助阐述本发明。优选实施例并没有详尽叙述所有的细节，也不限制该发明仅为所述的具体实施方式。显然，根据本说明书的内容，可作很多的修改和变化。本说明书选取并具体描述这些实施例，是为了更好地解释本发明的原理和实际应用，从而使所属技术领域技术人员能很好地理解和利用本发明。本发明仅受权利要求书及其全部范围和等效物的限制。
Claims (10)
1.一种含牛油果树果脂提取物成分的润肤护理组合物，其特征在于：由以下原料组成：皮肤调理剂、增稠剂、润肤剂、乳化剂、润肤剂一、润肤剂二、润肤剂三、润肤剂四和润肤剂五，其中，皮肤调理剂为牛油果树果脂提取物、刺阿干树仁油、废麦芽粕蜡和生育酚的混合，乳化剂为鲸蜡硬脂醇和鲸蜡硬脂基葡糖苷的混合。
2.根据权利要求1所述的一种含牛油果树果脂提取物成分的润肤护理组合物，其特征在于，增稠剂为鲸蜡硬脂醇，润肤剂一为辛酸/癸酸甘油三酯，润肤剂二为聚二甲基硅氧烷，润肤剂三为油橄榄果油，润肤剂四为聚二甲基硅氧烷/乙烯基聚二甲基硅氧烷交联聚合物，润肤剂五为角鲨烷。
3.根据权利要求2所述的一种含牛油果树果脂提取物成分的润肤护理组合物，其特征在于，以重量份计，由以下原料组成：
皮肤调理剂1-5份、鲸蜡硬脂醇1-5份、辛酸/癸酸甘油三酯1-5份、乳化剂1-5份、聚二甲基硅氧烷0.1-1份、油橄榄果油0.1-1份、聚二甲基硅氧烷/乙烯基聚二甲基硅氧烷交联聚合物0.1-1份和角鲨烷0.1-1份。
4.根据权利要求3所述的一种含牛油果树果脂提取物成分的润肤护理组合物，其特征在于，以重量份计，由以下原料组成：
皮肤调理剂1份、鲸蜡硬脂醇2份、辛酸/癸酸甘油三酯1份、乳化剂2份、聚二甲基硅氧烷1份、油橄榄果油0.2份、聚二甲基硅氧烷/乙烯基聚二甲基硅氧烷交联聚合物0.2份和角鲨烷0.2份。
5.根据权利要求3所述的一种含牛油果树果脂提取物成分的润肤护理组合物，其特征在于，以重量份计，由以下原料组成：
皮肤调理剂3份、鲸蜡硬脂醇2份、辛酸/癸酸甘油三酯2份、乳化剂2份、聚二甲基硅氧烷1份、油橄榄果油0.5份、聚二甲基硅氧烷/乙烯基聚二甲基硅氧烷交联聚合物0.5份和角鲨烷0.2份。
6.根据权利要求3所述的一种含牛油果树果脂提取物成分的润肤护理组合物，其特征在于，以重量份计，由以下原料组成：
皮肤调理剂5份、鲸蜡硬脂醇5份、辛酸/癸酸甘油三酯5份、乳化剂1份、聚二甲基硅氧烷0.5份、油橄榄果油0.6份、聚二甲基硅氧烷/乙烯基聚二甲基硅氧烷交联聚合物0.3份和角鲨烷0.2份。
7.根据权利要求1所述的一种含牛油果树果脂提取物成分的润肤护理组合物，其特征在于，所述皮肤调理剂为重量比（4-8）：（2-4）：（1-3）：2的牛油果树果脂提取物、刺阿干树仁油、废麦芽粕蜡和生育酚的混合。
8.根据权利要求1所述的一种含牛油果树果脂提取物成分的润肤护理组合物，其特征在于，所述乳化剂为重量比2：（3—5）的鲸蜡硬脂醇和鲸蜡硬脂基葡糖苷的混合。
9.根据权利要求1-8任一所述的一种含牛油果树果脂提取物成分的润肤护理组合物的应用，其特征在于，作为原料应用于润肤护理类化妆品中和应用于医用润肤类组合物中。
10.根据权利要求9所述的一种含牛油果树果脂提取物成分的润肤护理组合物的应用，其特征在于，作为原料应用于润肤护理乳液中。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310415440.2A CN116570538A (zh) | 2023-04-18 | 2023-04-18 | 一种含牛油果树果脂提取物成分的润肤护理组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310415440.2A CN116570538A (zh) | 2023-04-18 | 2023-04-18 | 一种含牛油果树果脂提取物成分的润肤护理组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116570538A true CN116570538A (zh) | 2023-08-11 |
Family
ID=87542264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310415440.2A Pending CN116570538A (zh) | 2023-04-18 | 2023-04-18 | 一种含牛油果树果脂提取物成分的润肤护理组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116570538A (zh) |
-
2023
- 2023-04-18 CN CN202310415440.2A patent/CN116570538A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112315882B (zh) | 一种舒缓修护保湿面霜及其制备方法 | |
| Michelle Garay et al. | Antiinflammatory activities of colloidal oatmeal (Avena sativa) contribute to the effectiveness of oats in treatment of itch associated with dry, irritated skin | |
| CN112118856A (zh) | 包含积雪草选择三萜的局部用护肤组合物 | |
| CN107049903B (zh) | 一种用于敏感肌肤的膏霜及其制备方法 | |
| CN111067828A (zh) | 用于抗敏修复的化妆品组合物 | |
| WO2024045952A1 (zh) | 含重组胶原蛋白具有修护舒缓功效的组合物、含有该组合物的眼霜及制备方法和应用 | |
| CN113143833A (zh) | 一种护肤品及其制备方法 | |
| Ferreira et al. | Sensitive skin: Active ingredients on the spotlight | |
| JP2010001264A (ja) | 神経伸長抑制剤 | |
| Chu et al. | An isoflavone extract from soybean cake suppresses 2, 4-dinitrochlorobenzene-induced contact dermatitis | |
| CN110025538B (zh) | 一种改善皮肤痤疮、炎症的组合物及其应用 | |
| CN113274445B (zh) | 一种具有缓解过敏性鼻炎症状的外用鼻膏的制备方法 | |
| KR101704539B1 (ko) | 기린초 추출물을 유효성분으로 포함하는 항알러지용 및 피부 보습용 조성물 | |
| CN116570538A (zh) | 一种含牛油果树果脂提取物成分的润肤护理组合物 | |
| KR102272237B1 (ko) | 천연물을 포함하는 아토피성 피부 개선 및 피부 보습용 조성물 | |
| KR101753687B1 (ko) | 목진피 추출물을 유효성분으로 포함하는 항알러지용 및 피부 보습용 조성물 | |
| CN116725906A (zh) | 一种含有青蒿挥发油的面霜及其应用 | |
| CN117815136A (zh) | 一种具有舒缓功效的保湿修护霜 | |
| KR20210148183A (ko) | 염증성 피부병을 위한 덱스트란 설페이트 | |
| CN112807238A (zh) | 一种皮肤抗炎舒缓修护凝胶及其制备方法 | |
| KR20110097462A (ko) | 산두근 추출물을 유효성분으로 함유하는 아토피 예방 또는 치료용 조성물 및 이의 제조방법 | |
| Farboud et al. | Avena sativa: an effective natural ingredient in herbal shampoos for the treatment of hair greasiness | |
| KR102334349B1 (ko) | 자일로올리고당을 유효성분으로 함유하는 피부자극완화용 화장료 조성물 | |
| CN116035979B (zh) | 一种舒缓修护组合物、精华液及其制备方法 | |
| CN115590791A (zh) | 一种具有改善面部泛红和滋润修复皮肤的乳液及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |